Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies Transcript
Welcome to the Proactive studios. I'm Natalie Stoberman, joined by the CEO of Tonix Pharmaceuticals, Seth Lederman. Seth, how are you doing today?
Thank you. Well, thanks for having me on.
Questions & Answers
Of course. It's a pleasure to have you on. And there are big news coming out of the company, but we're zoning in on something that has been around for a few months now, but because it's progressing and related to COVID-19, things change quickly. So with the new licensing agreement with Curia Global for monoclonal antibody treatment, where are we at with that agreement that came out in December?
Thank you, Natalie. We're excited about licensing these three monoclonal antibodies from Curia because
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
